Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Allogeneic umbilical cord blood cells refer to an investigational cellular therapy consisting of hematopoietic stem and progenitor cells, along with immune cells like T cells and natural killer (NK) cells, harvested from donor umbilical cord blood. In the context of clinical trials led by HOVON, this therapy is utilized in double umbilical cord blood transplantation (dUCBT), where two unrelated cord blood units are infused into patients with high-risk hematological malignancies who lack matched donors. The therapeutic effect is twofold: the transplanted stem cells reconstitute the patient's bone marrow, while the donor immune cells mediate a graft-versus-leukemia (GvL) effect to eliminate residual malignant cells.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on allogeneic umbilical cord blood cells (HOVON).